<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121666</url>
  </required_header>
  <id_info>
    <org_study_id>FIN3001</org_study_id>
    <secondary_id>2010-019287-37</secondary_id>
    <nct_id>NCT01121666</nct_id>
  </id_info>
  <brief_title>Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment</brief_title>
  <official_title>A Phase III Assessor-blinded Randomized Parallel Group Multi-centre Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA Versus Gonal-f) in Women for Assisted Reproductive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finox AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Finox AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ther purpose of this study is to show equivalence between AFOLIA and Gonal-f® with regard to
      the number of oocytes retrieved in women for assisted reproductive treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Oocytes Retrieved (Per Protocol Population)</measure>
    <time_frame>34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment</time_frame>
    <description>As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Oocytes Retrieved (Intention-to-treat Population)</measure>
    <time_frame>34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment</time_frame>
    <description>As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Size of Follicles ≥ 12 mm at Day 8 of Stimulation</measure>
    <time_frame>Day 8 of stimulation</time_frame>
    <description>The number and size of follicles 12 mm or over in diameter at day 8 of stimulation were evaluated as secondary end-point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E2 Concentration at Day 8 and at Day of hCG Administration</measure>
    <time_frame>Day 8 of stimulation and at the day of hCG administration (after max. 16 days of r-FSH treatment)</time_frame>
    <description>The serum concentration of oestradiol was assessed at day 8 and the day of hCG administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of r-hFSH Administered</measure>
    <time_frame>Day of hCG administration (after maximum 16 days of r-hFSH treatment)</time_frame>
    <description>Total dose of r-hFSH required was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Oocytes Retrieved</measure>
    <time_frame>34-36 hours after hCG administration</time_frame>
    <description>Number of patients with ovum pick-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilisation Rate of Oocytes</measure>
    <time_frame>1 day after ovum pick-up</time_frame>
    <description>Fertilisation rate was assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Quality: Mean Number of Blastomeres</measure>
    <time_frame>Day 2 of OPU/fertilisation</time_frame>
    <description>Main embryo quality parameter &quot;mean number of blastomeres&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cryopreserved 2PNs, Embryos/Blastocysts</measure>
    <time_frame>Day 1, 2, 3 and 5 of OPU/fertilisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of r-hFSH Stimulation</measure>
    <time_frame>At the day of hCG administration, up to 16 days</time_frame>
    <description>Mean duration of stimulation was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Cycle Cancellation</measure>
    <time_frame>Until child birth/miscarriage, up to the end of the study</time_frame>
    <description>Number of patients with cycle cancellation was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Good Response</measure>
    <time_frame>Until child birth/miscarriage, up to the end of the study</time_frame>
    <description>Good response was defined as &quot;patients with an oocyte retrieval of four or more oocytes&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>Five to six weeks after oocyte retrieval</time_frame>
    <description>Defined as fetal sac per embryo transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>Five to six weeks after oocyte retrieval</time_frame>
    <description>Presence of at least one intrauterine gestational sac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing Pregnancy</measure>
    <time_frame>Ten weeks after embryo transfer</time_frame>
    <description>Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>After childbirth with questionnaire</time_frame>
    <description>Patients with liveborn children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Quality: Absence of Multinucleation</measure>
    <time_frame>Day 3</time_frame>
    <description>Main embryo quality parameter &quot;absence of multinucleation&quot; observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Oocytes Retrieved</measure>
    <time_frame>At day 4 and 5</time_frame>
    <description>Number of patients with transferred blastocysts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Oocytes Retrieved</measure>
    <time_frame>Day of embryo transfer, either 2, 3 or 5 days after oocyte retrieval</time_frame>
    <description>Number of embryos per blastocysts transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate (Second Treatment Cycle)</measure>
    <time_frame>Five to six weeks after oocyte retrieval</time_frame>
    <description>Presence of at least one intrauterine gestational sac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing Pregnancy (Second Treatment Cycle)</measure>
    <time_frame>10 weeks after embryo transfer</time_frame>
    <description>Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Oocytes Retrieved</measure>
    <time_frame>After oocyte retrieval, 34 to 36 hours after hCG administration</time_frame>
    <description>The maturity of the cumulus oophorus was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Oocytes Retrieved</measure>
    <time_frame>After oocyte retrieval, 34 to 36 hours after hCG administration</time_frame>
    <description>The nuclear maturity was assessed (Germinal vesicle, Metaphase I, Metaphase II).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Gonal-f® (Follitropin alfa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AFOLIA-150 (Follitropin alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa</intervention_name>
    <description>150IU per day subcutaneously for a maximum of 16 days</description>
    <arm_group_label>Gonal-f® (Follitropin alfa)</arm_group_label>
    <arm_group_label>AFOLIA-150 (Follitropin alfa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 38 years with regular menstrual cycles of 25-35 days

          -  First or second cycle in the present series of ART

          -  BMI ≥ 18 ≤ 30 kg/m2

          -  Basal FSH &lt; 10 IU/L (cycle day 2-5)

          -  E2 levels &lt; 50pg/mL (&lt; 0.18 nmol/L) at the day of FSH administration

          -  Antral follicle count (AFC) ≥ 10 to ≤ 25 follicles (sum of both ovaries)

          -  Infertility due to any of the following factors: tubal factor, mild endometriosis
             (ASRM stage 1-2), male factor, unexplained infertility

          -  Presence of both ovaries and normal uterine cavity (confirmed by transvaginal
             ultrasound within 6 months before randomisation)

          -  Willingness to participate in the study and to comply with the study protocol

          -  Informed consent

        Exclusion Criteria:

          -  Presence of pregnancy

          -  History of ≥2 succeeding ART cycles (IVF and/or ICSI) before the study cycle without
             clinical pregnancy

          -  Presence of clinically significant systemic disease

          -  Presence of chronic cardiovascular, hepatic, renal or pulmonary disease

          -  Presence of uncontrolled endocrine disorder

          -  Previous history or presence of severe ovarian hyperstimulation syndrome

          -  Presence of polycystic ovaries (PCO)

          -  Presence of severe endometriosis (ASRM stage 3 or stage 4) and hydrosalpinx

          -  Neoplasia, including tumors of the hypothalamus and pituitary gland

          -  Abnormal bleeding of undetermined origin

          -  History of poor response to gonadotropin treatment (defined as fewer than 5 oocytes
             retrieved in a previous attempt)

          -  Male infertility without mobile spermatozoa in the ejaculate, that need testicular of
             epididymal sperm retrieval (MESA/TESE/TESA)

          -  Endocrine abnormality such as TSH or prolactin level elevations outside the reference
             range if clinically relevant at screening

          -  Any hormonal treatment within 1 month before the start of the FSH treatment (with the
             exception of levothyroxin)

          -  History of drug, nicotine or alcohol abuse within the last 12 months (&gt; 10
             cigarettes/day)

          -  Administration of other investigational products within the last month

          -  Clinically abnormal findings at Visit 1

          -  Planned PGS/PGD/PBB or assisted hatching

          -  Concomitant participation in an other study protocol

          -  History of extrauterine pregnancy in the previous 3 months

          -  Known allergy or hypersensitivity to progesterone or to any of the excipients
             (including peanut oil) of the additional study medication (GnRH agonist, vitrelle®,
             and Utrogestan®)

          -  Presence or history of thrombophlebitis or thromboembolic disorders

          -  Presence or history of cerebral haemorrhage

          -  Presence or history of porphyria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Imthurn</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinderwunsch Institut Schenk GmbH</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Frauenklinik und Kinderklinik Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF Zentrum Döbling</name>
      <address>
        <city>Vienna</city>
        <zip>11920</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatspital Goldenes Kreuz</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Clinic</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen Fertility Center</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dansk Fertilitetsklinik</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Barthlomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>February 17, 2016</results_first_submitted>
  <results_first_submitted_qc>March 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Assisted reproductive treatment</keyword>
  <keyword>Superovulation</keyword>
  <keyword>Follitropin alfa</keyword>
  <keyword>r-hFSH</keyword>
  <keyword>AFOLIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 15 centers in six European countries from July 2010 until April 2012.</recruitment_details>
      <pre_assignment_details>Of 460 participants in this trial 88 were reported as screening failures prior the group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AFOLIA-150 (Follitropin Alfa)</title>
          <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
        </group>
        <group group_id="P2">
          <title>Gonal-f® (Follitropin Alfa)</title>
          <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AFOLIA-150 (Follitropin Alfa)</title>
          <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
        </group>
        <group group_id="B2">
          <title>Gonal-f® (Follitropin Alfa)</title>
          <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="372"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="4.02"/>
                    <measurement group_id="B2" value="32.1" spread="3.76"/>
                    <measurement group_id="B3" value="31.95" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FSH baseline concentration</title>
          <description>The FSH concentration was measured at baseline in IU/L.</description>
          <units>(IU/L)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" lower_limit="2.5" upper_limit="17.1"/>
                    <measurement group_id="B2" value="6.9" lower_limit="2.8" upper_limit="10"/>
                    <measurement group_id="B3" value="6.9" lower_limit="2.5" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antral follicle count</title>
          <units>Antral follicle count</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.1" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="B2" value="15.3" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="B3" value="15.2" lower_limit="10" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogramm/ square meter</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.7" lower_limit="18.0" upper_limit="30.3"/>
                    <measurement group_id="B2" value="22.4" lower_limit="18.2" upper_limit="28.7"/>
                    <measurement group_id="B3" value="22.6" lower_limit="18.0" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GnRH-agonist duration</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" lower_limit="11.0" upper_limit="44.0"/>
                    <measurement group_id="B2" value="22.7" lower_limit="12.0" upper_limit="46.0"/>
                    <measurement group_id="B3" value="23.1" lower_limit="11.0" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AMH less than 24 pmol/L</title>
          <description>Number of patients of each group who had a lower AMH level than 24 pmol/L. The cut-off level was defined on the basis of the evaluated level published previously.</description>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Oocytes Retrieved (Per Protocol Population)</title>
        <description>As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes</description>
        <time_frame>34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved (Per Protocol Population)</title>
          <description>As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes</description>
          <population>Per protocol population</population>
          <units>Number of retrieved oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="5.11"/>
                    <measurement group_id="O2" value="10.6" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was powered to test equivalence using a two one-sided test (TOST) of the number of oocytes retrieved.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study was powered to test equivalence using a two one-sided test (TOST) of the number of oocytes retrieved with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <p_value_desc>This study was powered to test equivalence using a two one-sided test (TOST) with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population.</p_value_desc>
            <method>Shuirmann’s TOST</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Size of Follicles ≥ 12 mm at Day 8 of Stimulation</title>
        <description>The number and size of follicles 12 mm or over in diameter at day 8 of stimulation were evaluated as secondary end-point.</description>
        <time_frame>Day 8 of stimulation</time_frame>
        <population>All participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Size of Follicles ≥ 12 mm at Day 8 of Stimulation</title>
          <description>The number and size of follicles 12 mm or over in diameter at day 8 of stimulation were evaluated as secondary end-point.</description>
          <population>All participants were analyzed.</population>
          <units>Number of follicles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 12 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="4.73"/>
                    <measurement group_id="O2" value="11.1" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 15 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="3.81"/>
                    <measurement group_id="O2" value="7.7" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 17 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="3.29"/>
                    <measurement group_id="O2" value="4.5" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2357</p_value>
            <p_value_desc>Follicles of 12 mm</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1395</p_value>
            <p_value_desc>Follicles of 15 mm</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>Follicles of 17 mm</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E2 Concentration at Day 8 and at Day of hCG Administration</title>
        <description>The serum concentration of oestradiol was assessed at day 8 and the day of hCG administration.</description>
        <time_frame>Day 8 of stimulation and at the day of hCG administration (after max. 16 days of r-FSH treatment)</time_frame>
        <population>All participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>E2 Concentration at Day 8 and at Day of hCG Administration</title>
          <description>The serum concentration of oestradiol was assessed at day 8 and the day of hCG administration.</description>
          <population>All participants were analyzed.</population>
          <units>pmol/ L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day of hCG administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8982.3" spread="6535.3"/>
                    <measurement group_id="O2" value="7704.2" spread="5345.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3958.9" spread="3699.4"/>
                    <measurement group_id="O2" value="3234.0" spread="2428.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of r-hFSH Administered</title>
        <description>Total dose of r-hFSH required was assessed.</description>
        <time_frame>Day of hCG administration (after maximum 16 days of r-hFSH treatment)</time_frame>
        <population>All participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of r-hFSH Administered</title>
          <description>Total dose of r-hFSH required was assessed.</description>
          <population>All participants were analyzed.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1555.7" spread="293.00"/>
                    <measurement group_id="O2" value="1569.2" spread="259.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9638</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Oocytes Retrieved</title>
        <description>Number of patients with ovum pick-up</description>
        <time_frame>34-36 hours after hCG administration</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Oocytes Retrieved</title>
          <description>Number of patients with ovum pick-up</description>
          <population>Intention to treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilisation Rate of Oocytes</title>
        <description>Fertilisation rate was assessed</description>
        <time_frame>1 day after ovum pick-up</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilisation Rate of Oocytes</title>
          <description>Fertilisation rate was assessed</description>
          <population>Intention to treat population</population>
          <units>percentage of oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="24.84"/>
                    <measurement group_id="O2" value="64.0" spread="24.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Quality: Mean Number of Blastomeres</title>
        <description>Main embryo quality parameter &quot;mean number of blastomeres&quot;</description>
        <time_frame>Day 2 of OPU/fertilisation</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Quality: Mean Number of Blastomeres</title>
          <description>Main embryo quality parameter &quot;mean number of blastomeres&quot;</description>
          <population>Intention to treat population</population>
          <units>Number of blastomeres at day 3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.41"/>
                    <measurement group_id="O2" value="6.4" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cryopreserved 2PNs, Embryos/Blastocysts</title>
        <time_frame>Day 1, 2, 3 and 5 of OPU/fertilisation</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cryopreserved 2PNs, Embryos/Blastocysts</title>
          <population>Intention to treat population</population>
          <units>Patients with cryopreservation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of r-hFSH Stimulation</title>
        <description>Mean duration of stimulation was assessed.</description>
        <time_frame>At the day of hCG administration, up to 16 days</time_frame>
        <population>All participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of r-hFSH Stimulation</title>
          <description>Mean duration of stimulation was assessed.</description>
          <population>All participants were analyzed.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="1.91"/>
                    <measurement group_id="O2" value="10.7" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8926</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Cycle Cancellation</title>
        <description>Number of patients with cycle cancellation was assessed.</description>
        <time_frame>Until child birth/miscarriage, up to the end of the study</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cycle Cancellation</title>
          <description>Number of patients with cycle cancellation was assessed.</description>
          <population>Intention to treat population</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Good Response</title>
        <description>Good response was defined as &quot;patients with an oocyte retrieval of four or more oocytes&quot;</description>
        <time_frame>Until child birth/miscarriage, up to the end of the study</time_frame>
        <population>Intention to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Good Response</title>
          <description>Good response was defined as &quot;patients with an oocyte retrieval of four or more oocytes&quot;</description>
          <population>Intention to treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implantation Rate</title>
        <description>Defined as fetal sac per embryo transferred.</description>
        <time_frame>Five to six weeks after oocyte retrieval</time_frame>
        <population>Intention to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Implantation Rate</title>
          <description>Defined as fetal sac per embryo transferred.</description>
          <population>Intention to treat population.</population>
          <units>Percentage of implantations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>Presence of at least one intrauterine gestational sac.</description>
        <time_frame>Five to six weeks after oocyte retrieval</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>Presence of at least one intrauterine gestational sac.</description>
          <population>Intention to treat population</population>
          <units>Clinical pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ongoing Pregnancy</title>
        <description>Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.</description>
        <time_frame>Ten weeks after embryo transfer</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Pregnancy</title>
          <description>Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.</description>
          <population>Intention to treat population</population>
          <units>Ongoing pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth Rate</title>
        <description>Patients with liveborn children</description>
        <time_frame>After childbirth with questionnaire</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <description>Patients with liveborn children</description>
          <population>Intention to treat population</population>
          <units>Patients with liveborn children</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Oocytes Retrieved (Intention-to-treat Population)</title>
        <description>As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes</description>
        <time_frame>34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment</time_frame>
        <population>Intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved (Intention-to-treat Population)</title>
          <description>As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes</description>
          <population>Intention-to-treat population</population>
          <units>Number of retrieved oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.62"/>
                    <measurement group_id="O2" value="10.4" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study was powered to test equivalence using a two one-sided test (TOST) of the number of oocytes retrieved with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>Shuirmann’s TOST</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Quality: Absence of Multinucleation</title>
        <description>Main embryo quality parameter &quot;absence of multinucleation&quot; observed.</description>
        <time_frame>Day 3</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Quality: Absence of Multinucleation</title>
          <description>Main embryo quality parameter &quot;absence of multinucleation&quot; observed.</description>
          <population>Intention to treat population</population>
          <units>Percentage of absent multinucleation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6"/>
                    <measurement group_id="O2" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Oocytes Retrieved</title>
        <description>Number of patients with transferred blastocysts</description>
        <time_frame>At day 4 and 5</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Oocytes Retrieved</title>
          <description>Number of patients with transferred blastocysts</description>
          <population>Intention to treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Oocytes Retrieved</title>
        <description>Number of embryos per blastocysts transferred</description>
        <time_frame>Day of embryo transfer, either 2, 3 or 5 days after oocyte retrieval</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Oocytes Retrieved</title>
          <description>Number of embryos per blastocysts transferred</description>
          <population>Intention to treat population</population>
          <units>embryos per blastocysts transferred</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.52"/>
                    <measurement group_id="O2" value="1.6" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate (Second Treatment Cycle)</title>
        <description>Presence of at least one intrauterine gestational sac.</description>
        <time_frame>Five to six weeks after oocyte retrieval</time_frame>
        <population>Population with a second treatment cycle</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate (Second Treatment Cycle)</title>
          <description>Presence of at least one intrauterine gestational sac.</description>
          <population>Population with a second treatment cycle</population>
          <units>Clinical pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ongoing Pregnancy (Second Treatment Cycle)</title>
        <description>Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.</description>
        <time_frame>10 weeks after embryo transfer</time_frame>
        <population>Population with a second treatment cycle</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Pregnancy (Second Treatment Cycle)</title>
          <description>Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.</description>
          <population>Population with a second treatment cycle</population>
          <units>Ongoing pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Oocytes Retrieved</title>
        <description>The maturity of the cumulus oophorus was assessed.</description>
        <time_frame>After oocyte retrieval, 34 to 36 hours after hCG administration</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Oocytes Retrieved</title>
          <description>The maturity of the cumulus oophorus was assessed.</description>
          <population>Intention to treat population</population>
          <units>Percentage of cumulus oophori</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>very mature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7"/>
                    <measurement group_id="O2" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>immature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Oocytes Retrieved</title>
        <description>The nuclear maturity was assessed (Germinal vesicle, Metaphase I, Metaphase II).</description>
        <time_frame>After oocyte retrieval, 34 to 36 hours after hCG administration</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>AFOLIA-150 (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f® (Follitropin Alfa)</title>
            <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Oocytes Retrieved</title>
          <description>The nuclear maturity was assessed (Germinal vesicle, Metaphase I, Metaphase II).</description>
          <population>Intention to treat population</population>
          <units>Percentage of cells</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Germinal vesicle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metaphase I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metaphase II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period + 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AFOLIA-150 (Follitropin Alfa)</title>
          <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
        </group>
        <group group_id="E2">
          <title>Gonal-f® (Follitropin Alfa)</title>
          <description>Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temparature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Melanie Ruf</name_or_title>
      <organization>Five Office Ltd</organization>
      <phone>+41 44 9324132</phone>
      <email>clin@five.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

